Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Major Adverse Cardiovascular Events During Invasive Pneumococcal Disease Are Serotype Dependent.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Pooled it
- Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis.Critical care (London, England) · 2023Trial
- Burden of Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Adults: Significant Adverse Outcomes and Costs beyond Direct Treatment.Infectious diseases and therapy · 2026Article
- Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review.Vaccines · 2026Review
- Cost-utility of pneumococcal strategies for adults aged 50 and older in Colombia: a model-based economic evaluation.BMC health services research · 2026Article
- Preliminary genomic assessment of invasive Streptococcus pneumoniae serotype 3 isolates in Malaysia.BMC genomic data · 2026Article
- Article
- Emergence of multidrug-resistant ST876 serotype 14Frontiers in cellular and infection microbiology · 2026Article
- Allele-specific zinc metalloprotease B influences cardiac damage during invasive pneumococcal disease.Cell reports · 2025Article
- Global distribution and characteristics of pneumococcal serotypes in adults.Human vaccines & immunotherapeutics · 2025Review
- Within-host genetic diversity of pneumococcal serotype 3 during one-year prolonged carriage in a healthy adult.Nature communications · 2025Article
- Review
- Infectious diseases, cardio-cerebrovascular health and vaccines: pathways to prevention.Aging clinical and experimental research · 2025Review
- Frequency and Mortality of Adult Meningitis, Pneumonia, or Bacteremia in Colombia from 2015 to 2022: A Retrospective Database Study in a Health Maintenance Organization.Journal of health economics and outcomes research · 2025Article
- Serotype 3 pneumococcal pleural empyema: a case report and review of the epidemiology.European clinical respiratory journal · 2025Article
- Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).Scientific reports · 2024Article
- Arterial Thrombosis in Acute Respiratory Infections: An Underestimated but Clinically Relevant Problem.Journal of clinical medicine · 2024Review
- Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study.The Lancet regional health. Europe · 2024Article
- Bacterial Pneumonia and Stroke Risk: A Nationwide Longitudinal Followup Study.Current neurovascular research · 2024Article
- A Multicentric Observational Study to Determine Myocardial Injury in Severe Community-Acquired Pneumonia (sCAP).Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundUp to 30% of patients admitted to hospitals with invasive pneumococcal disease (IPD) experience major adverse cardiovascular event (MACE) including new/worsening heart failure, new/worsening arrhythmia, and/or myocardial infarction. Streptococcus pneumoniae (Spn) is the most frequently isolated bacterial pathogen among community-acquired pneumonia (CAP) patients and the only etiological agent linked independently to MACE. Nevertheless, no clinical data exist identifying which serotypes of Spn are principally responsible for MACE.
methodsThis was an observational multicenter retrospective study conducted through the Public Health Secretary of Bogotá, Colombia. We included patients with a confirmed clinical diagnosis of IPD with record of pneumococcal serotyping and clinical information between 2012 and 2019. Spn were serotyped using the quellung method by the National Center of Microbiology. MACE were determined by a retrospective chart review.
resultsThe prevalence of MACE was 23% (71/310) in IPD patients and 28% (53/181) in patients admitted for CAP. The most prevalent S. pneumoniae serotype identified in our study was the 19A, responsible for the 13% (42/310) of IPD in our cohort, of which 21% (9/42) presented MACE. Serotypes independently associated with MACE in IPD patients were serotype 3 (odds ratio [OR] 1, 48; 95% confidence interval [CI] [1.21-2.27]; P = .013) and serotype 9n (OR 1.29; 95% CI [1.08-2.24]; P = .020). Bacteremia occurred in 87% of patients with MACE. Moreover, serum concentrations of C-reactive protein were elevated in patients with MACE versus in non-MACE patients (mean [standard deviation], 138 [145] vs 73 [106], P = .01).
conclusionsMACE are common during IPD with serotype 3 and 9n independently of frequency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.